Strategic Account Executive

Streck supports HopeScan Initiative with charitable donation to expand access to cancer diagnostics in West Africa. August 19, 2026 LA VISTA, Neb., and UPPER MARLBORO, Md. - Streck, a leader in sample stabilization and quality control solutions for clinical and research laboratories, has made a charitable donation to HopeScan Initiative, Inc. HopeScan is a U.S.-based 501(c)(3) nonprofit working to expand access to cancer screening, diagnostic services and care in underserved communities across sub-Saharan West Africa. The donation will support HopeScan's efforts to strengthen access to diagnostic services and help connect communities with pathways to appropriate follow-up care. The contribution reflects a shared belief that advances in diagnostic technology should have the opportunity to benefit patients and communities regardless of geography or access to healthcare resources. "Streck is proud to support HopeScan's mission to expand access to next-generation diagnostic testing in underserved communities," said Dara Wright, Chief Executive Officer and President, Streck. "We believe broader access to innovative diagnostic technologies has the potential to provide clinicians with valuable insights and, ultimately, help improve the lives of patients and their communities." For more than 50 years, Streck has developed technologies designed to preserve sample integrity and support reliable laboratory testing. Its blood collection and stabilization technologies are used in research and clinical workflows around the world, including applications supporting the rapidly evolving fields of liquid biopsy and molecular diagnostics. HopeScan works with healthcare providers and communities to address barriers that can limit access to cancer screening and diagnostic services. Streck's contribution will help advance HopeScan's work in West Africa and support its broader mission of bringing advances in cancer diagnostics to communities where access remains limited. "We are incredibly grateful to Streck for its generous financial contribution, which will help expand access to cervical cancer screening and care in Nigeria," said Dr. Omoshile Clement, Executive Director of HopeScan Initiative Inc. "By supporting the purchase of HPV DNA testing and patient specimen collection kits, Streck is helping us reach more women with the opportunity for early detection and timely care - an important step toward reducing the burden of cervical cancer in underserved communities." About Streck Established in 1971, Streck provides solutions that ensure every result counts by empowering clinical and research laboratories to reliably deliver accurate results, advance diagnostics, and enable healthier, happier lives for patients everywhere. Streck products are manufactured in La Vista, Nebraska, and delivered to thousands of labs worldwide. About HopeScan Initiative, Inc. HopeScan Initiative, Inc. is a 501(c)(3) nonprofit organization advancing equitable access to cancer awareness, early detection, confirmatory diagnosis, and navigated care in underserved communities across sub-Saharan West Africa. Through partnerships with trusted cancer specialists, hospital networks and local community engagement, HopeScan helps bridge the gap between disease onset and care by supporting early screening, diagnostic confirmation, patient navigation, treatment referral, and follow-up care. Initially focused on breast, cervical, and prostate cancers, HopeScan is committed to building sustainable pathways to prevention and care as well as strengthening local capacity so that access to life-saving cancer detection and treatment are not determined by geography or socioeconomic status. Learn more at hopescan-initiative.org.

Streck gets IVD clearance for MDx-Chex controls, launches blood culture tube. May 19, 2026 - Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing. MDx-Chex for BCY, MDx-Chex for BCP, and MDx-Chex for BCN are patient-like, ready-to-use, full-process molecular quality controls designed for verification of the Diasorin Liaison Plex yeast, Gram-positive, and Gram-negative blood culture assays, respectively. The controls are supplied in 10 single-use vial kits and feature room temperature storage. In a separate release, Streck announced the launch of its Nucleic Acid Plus BCT blood collection tube. Formerly known as Protein Plus BCT, this product has expanded its intended use claims to include cell-free DNA, cell-free RNA, extracellular vesicles, and select plasma proteins in an aim to better suit downstream multianalyte applications. Nucleic Acid Plus BCT provides stabilization of whole blood samples at ambient temperature (18°-25°C), with cfDNA and cfRNA remaining stable in stored samples for up to seven days and EVs and select plasma proteins remaining stable for up to five days. This allows for multianalyte analysis from a single draw. The tube's proprietary preservative reagent stabilizes nucleated blood cells, red blood cells, and platelets while minimizing ex vivo hemolysis and platelet activation. Nucleic Acid Plus BCT is for research use only and available as a 5-mL configuration in packs of six, boxes of 100, or cases of 1,000. A 10-mL configuration is expected to launch later this year.